Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Shares Outstanding (Diluted Average): 2019-2025

Historic Shares Outstanding (Diluted Average) for Cartesian Therapeutics (RNAC) over the last 6 years, with Sep 2025 value amounting to $26.0 million.

  • Cartesian Therapeutics' Shares Outstanding (Diluted Average) rose 21.10% to $26.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.0 million, marking a year-over-year increase of 21.10%. This contributed to the annual value of $17.4 million for FY2024, which is 235.72% up from last year.
  • Latest data reveals that Cartesian Therapeutics reported Shares Outstanding (Diluted Average) of $26.0 million as of Q3 2025, which was down 1.68% from $26.4 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Shares Outstanding (Diluted Average) ranged from a high of $152.8 million in Q3 2022 and a low of $5.1 million during Q1 2023.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $17.4 million (2024), whereas its average is $14.6 million.
  • As far as peak fluctuations go, Cartesian Therapeutics' Shares Outstanding (Diluted Average) slumped by 96.62% in 2023, and later soared by 378.44% in 2025.
  • Quarterly analysis of 5 years shows Cartesian Therapeutics' Shares Outstanding (Diluted Average) stood at $114.3 million in 2021, then increased by 27.59% to $145.9 million in 2022, then crashed by 96.46% to $5.2 million in 2023, then spiked by 235.72% to $17.4 million in 2024, then climbed by 21.10% to $26.0 million in 2025.
  • Its last three reported values are $26.0 million in Q3 2025, $26.4 million for Q2 2025, and $25.9 million during Q1 2025.